These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25824212)

  • 21. Development of UV/HPLC methods for quantitative analysis of benznidazole in human plasma and urine for application in pediatric clinical studies.
    Marsón ME; Dana DD; Altcheh J; García-Bournissen F; Mastrantonio G
    J Clin Lab Anal; 2013 Sep; 27(5):384-90. PubMed ID: 24038224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical pharmacokinetics of benznidazole-loaded interpolyelectrolyte complex-based delivery systems.
    García MC; Guzman ML; Himelfarb MA; Litterio NJ; Olivera ME; Jimenez-Kairuz A
    Eur J Pharm Sci; 2018 Sep; 122():281-291. PubMed ID: 30018011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extemporaneous benznidazole oral suspension prepared from commercially available tablets for treatment of Chagas disease in paediatric patients.
    García MC; Manzo RH; Jimenez-Kairuz AF
    Trop Med Int Health; 2015 Jul; 20(7):864-70. PubMed ID: 25784402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method.
    Moreira da Silva R; Oliveira LT; Silva Barcellos NM; de Souza J; de Lana M
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3344-8. PubMed ID: 22450981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benznidazole microcrystal preparation by solvent change precipitation and in vivo evaluation in the treatment of Chagas disease.
    Maximiano FP; de Paula LM; Figueiredo VP; de Andrade IM; Talvani A; Sá-Barreto LC; Bahia MT; Cunha-Filho MS
    Eur J Pharm Biopharm; 2011 Aug; 78(3):377-84. PubMed ID: 21397015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies.
    Scalise ML; Arrúa EC; Rial MS; Esteva MI; Salomon CJ; Fichera LE
    Am J Trop Med Hyg; 2016 Aug; 95(2):388-93. PubMed ID: 27246447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.
    Li X; Yi S; Scariot DB; Martinez SJ; Falk BA; Olson CL; Romano PS; Scott EA; Engman DM
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33986194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study.
    Davanço MG; Campos ML; Rosa TA; Padilha EC; Alzate AH; Rolim LA; Rolim-Neto PJ; Peccinini RG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2492-8. PubMed ID: 26883698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid and sensitive ultra-high-pressure liquid chromatography method for quantification of antichagasic benznidazole in plasma: application in a preclinical pharmacokinetic study.
    Davanço MG; de Campos ML; Peccinini RG
    Biomed Chromatogr; 2015 Jul; 29(7):1008-15. PubMed ID: 25424984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benznidazole in vitro dissolution release from a pH-sensitive drug delivery system using Zif-8 as a carrier.
    de Moura Ferraz LR; Tabosa AÉGA; da Silva Nascimento DDS; Ferreira AS; Silva JYR; Junior SA; Rolim LA; Rolim-Neto PJ
    J Mater Sci Mater Med; 2021 May; 32(6):59. PubMed ID: 33999312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency Variation and Dose Modification of Benznidazole Administration for the Treatment of Trypanosoma cruzi Infection in Mice, Dogs, and Nonhuman Primates.
    Bustamante JM; White BE; Wilkerson GK; Hodo CL; Auckland LD; Wang W; McCain S; Hamer SA; Saunders AB; Tarleton RL
    Antimicrob Agents Chemother; 2023 May; 67(5):e0013223. PubMed ID: 37039666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.
    Pinazo MJ; Guerrero L; Posada E; Rodríguez E; Soy D; Gascon J
    Antimicrob Agents Chemother; 2013 Jan; 57(1):390-5. PubMed ID: 23114763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment.
    Aldasoro E; Posada E; Requena-Méndez A; Calvo-Cano A; Serret N; Casellas A; Sanz S; Soy D; Pinazo MJ; Gascon J
    J Antimicrob Chemother; 2018 Apr; 73(4):1060-1067. PubMed ID: 29351667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará].
    de Pontes VM; Souza Júnior AS; Cruz FM; Coelho HL; Dias AT; Coêlho IC; Oliveira Mde F
    Rev Soc Bras Med Trop; 2010; 43(2):182-7. PubMed ID: 20464150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.
    Garcia-Bournissen F; Altcheh J; Giglio N; Mastrantonio G; Della Védova CO; Koren G
    Paediatr Drugs; 2009; 11(1):33-7. PubMed ID: 19127950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole.
    Watson JA; Strub-Wourgraft N; Tarral A; Ribeiro I; Tarning J; White NJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.
    Leite DI; Fontes FV; Bastos MM; Hoelz LVB; Bianco MDCAD; de Oliveira AP; da Silva PB; da Silva CF; Batista DDGJ; da Gama ANS; Peres RB; Villar JDF; Soeiro MNC; Boechat N
    Chem Biol Drug Des; 2018 Sep; 92(3):1670-1682. PubMed ID: 29745048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection.
    Nguyen DM; Poveda C; Pollet J; Gusovsky F; Bottazzi ME; Hotez PJ; Jones KM
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011519. PubMed ID: 37988389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.